To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence Score®), we determined whether women with HER2(−)/ER+ pN1mi breast cancer with low ( vs. 57.9% in the intermediate-risk group and 100% in the high-risk group (p < 0.001). A total of 80.2% of the low-risk group were recommended endocrine therapy alone, while 77.8% of the high-risk group were recommended both endocrine and chemotherapy (p < 0.001). The Oncotype DX Recurrence Score result provides actionable information that can be incorporated into treatment planning for women with HER2(−)/ER+ pN1mi breast cancer. The Recurrence Score result has clinical utility in treatment planning for HER2(−)/ER+ pN1mi breast cancer patients.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Frazier, T.G.; Fox, K.R.; Smith, J.S.; Laronga, C.; McSwain, A.; Paul, D.; Schultz, M.; Stilwill, J.; Teal, C.; Weisberg, T.; Vacchino, J.F.; Sing, A.P.; Cherepanov, D.; Hsiao, W.; Chang, E.; Broder, M.S. (2015) A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer, Pharmaceuticals 8(1):107-122. doi:10.3390/ph8010107